Argo Wealth Advisory LLC Purchases New Shares in Amgen Inc. $AMGN

Key Points

• Argo Wealth Advisory LLC bought a new position of 8,130 shares of Amgen in Q4, valued at about $2.66 million, representing 1.6% of its portfolio and the firm's 22nd largest holding.
• Amgen beat Q4 estimates with EPS $5.29 (consensus $4.76) and revenue $9.87B (consensus $9.46B), and set FY2026 guidance of 21.60–23.00 EPS; the stock's consensus analyst rating is "Hold" with an average target of $356.24.
• The company declared a quarterly dividend of $2.52 (annualized $10.08, yield 2.9%, ex-dividend May 15) and trades with a market cap of about $188.6B and a PE of 24.55.

Argo Wealth Advisory LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 8,130 shares of the medical research company's stock, valued at approximately $2,661,000. Amgen makes up 1.6% of Argo Wealth Advisory LLC's portfolio, making the stock its 22nd largest holding.

Several other hedge funds also recently added to or reduced their stakes in AMGN. West Wealth Group LLC bought a new stake in shares of Amgen during the 4th quarter worth about $207,000. Key Capital Management INC acquired a new position in shares of Amgen in the 4th quarter worth approximately $148,000. Slow Capital Inc. increased its position in shares of Amgen by 0.7% in the fourth quarter. Slow Capital Inc. now owns 12,579 shares of the medical research company's stock worth $4,117,000 after acquiring an additional 92 shares in the last quarter. PDS Planning Inc increased its position in shares of Amgen by 15.2% in the fourth quarter. PDS Planning Inc now owns 3,290 shares of the medical research company's stock worth $1,077,000 after acquiring an additional 435 shares in the last quarter. Finally, Nations Financial Group Inc. IA ADV increased its position in shares of Amgen by 0.6% in the fourth quarter. Nations Financial Group Inc. IA ADV now owns 16,706 shares of the medical research company's stock worth $5,468,000 after acquiring an additional 100 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

NASDAQ:AMGN opened at $349.39 on Friday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The firm has a fifty day simple moving average of $363.49 and a 200 day simple moving average of $336.75. The stock has a market capitalization of $188.56 billion, a PE ratio of 24.55, a P/E/G ratio of 3.28 and a beta of 0.47.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter last year, the firm posted $5.31 EPS. The company's quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's payout ratio is 70.84%.

Analysts Set New Price Targets

AMGN has been the subject of several research reports. TD Cowen restated a "buy" rating on shares of Amgen in a report on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Amgen from $285.00 to $295.00 and gave the stock a "hold" rating in a research note on Thursday, February 5th. Truist Financial boosted their target price on shares of Amgen from $318.00 to $319.00 and gave the stock a "hold" rating in a research report on Thursday, January 8th. Argus boosted their price target on shares of Amgen from $360.00 to $400.00 and gave the company a "buy" rating in a report on Friday, February 6th. Finally, Mizuho upped their target price on shares of Amgen from $280.00 to $295.00 and gave the stock an "outperform" rating in a report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $356.24.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.